Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells

Monika Toth, I. Boros, E. Bálint

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Failure of chemotherapy in breast cancer presents a major problem and is often due to elevated expression of ATP binding cassette (ABC)-type transporters, such as MDR1 protein. It has been shown that MDR1/ABCB1 gene expression is regulated at the chromatin level by DNA methylation and histone acetylation. However, the modified histone residues have not been identified and the role of various histone acetyl transferases (HATs) is not fully understood. By studying a breast carcinoma model cell line and its MDR1-overexpressing derivative, we show that the histone 3 lysine 9 (H3K9) acetylation level is elevated 100-fold in the promoter and first exon of the MDR1 gene in the drug-resistant cell line compared to the drug-sensitive cell line. The acetylation level of the other examined lysine residues (H3K4, H3K14, H4K8, and H4K12) is weakly or not at all elevated in the MDR1 locus, although their acetylation is generally increased genome-wide in the drug-resistant cell. Downregulation of the expression of HATs PCAF and GCN5 by RNAi effectively reduces the expression of MDR1. Unexpectedly, treatment with a p300-selective inhibitor (HAT inhibitor II) further increases MDR1 expression and drug efflux in the drug-resistant cells. Our data suggest that repeated exposure to chemotherapy may result in deregulated histone acetylation genome-wide and in the MDR1 promoter.

Original languageEnglish
Pages (from-to)659-669
Number of pages11
JournalCancer Science
Volume103
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Histones
Lysine
Acetylation
Transferases
Pharmaceutical Preparations
Cell Line
Genome
Breast Neoplasms
Drug Therapy
ATP-Binding Cassette Transporters
P-Glycoprotein
DNA Methylation
RNA Interference
Chromatin
Exons
Down-Regulation
Gene Expression
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells. / Toth, Monika; Boros, I.; Bálint, E.

In: Cancer Science, Vol. 103, No. 4, 04.2012, p. 659-669.

Research output: Contribution to journalArticle

@article{55d43fd1b790481fad8a59751c3d5adb,
title = "Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells",
abstract = "Failure of chemotherapy in breast cancer presents a major problem and is often due to elevated expression of ATP binding cassette (ABC)-type transporters, such as MDR1 protein. It has been shown that MDR1/ABCB1 gene expression is regulated at the chromatin level by DNA methylation and histone acetylation. However, the modified histone residues have not been identified and the role of various histone acetyl transferases (HATs) is not fully understood. By studying a breast carcinoma model cell line and its MDR1-overexpressing derivative, we show that the histone 3 lysine 9 (H3K9) acetylation level is elevated 100-fold in the promoter and first exon of the MDR1 gene in the drug-resistant cell line compared to the drug-sensitive cell line. The acetylation level of the other examined lysine residues (H3K4, H3K14, H4K8, and H4K12) is weakly or not at all elevated in the MDR1 locus, although their acetylation is generally increased genome-wide in the drug-resistant cell. Downregulation of the expression of HATs PCAF and GCN5 by RNAi effectively reduces the expression of MDR1. Unexpectedly, treatment with a p300-selective inhibitor (HAT inhibitor II) further increases MDR1 expression and drug efflux in the drug-resistant cells. Our data suggest that repeated exposure to chemotherapy may result in deregulated histone acetylation genome-wide and in the MDR1 promoter.",
author = "Monika Toth and I. Boros and E. B{\'a}lint",
year = "2012",
month = "4",
doi = "10.1111/j.1349-7006.2012.02215.x",
language = "English",
volume = "103",
pages = "659--669",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells

AU - Toth, Monika

AU - Boros, I.

AU - Bálint, E.

PY - 2012/4

Y1 - 2012/4

N2 - Failure of chemotherapy in breast cancer presents a major problem and is often due to elevated expression of ATP binding cassette (ABC)-type transporters, such as MDR1 protein. It has been shown that MDR1/ABCB1 gene expression is regulated at the chromatin level by DNA methylation and histone acetylation. However, the modified histone residues have not been identified and the role of various histone acetyl transferases (HATs) is not fully understood. By studying a breast carcinoma model cell line and its MDR1-overexpressing derivative, we show that the histone 3 lysine 9 (H3K9) acetylation level is elevated 100-fold in the promoter and first exon of the MDR1 gene in the drug-resistant cell line compared to the drug-sensitive cell line. The acetylation level of the other examined lysine residues (H3K4, H3K14, H4K8, and H4K12) is weakly or not at all elevated in the MDR1 locus, although their acetylation is generally increased genome-wide in the drug-resistant cell. Downregulation of the expression of HATs PCAF and GCN5 by RNAi effectively reduces the expression of MDR1. Unexpectedly, treatment with a p300-selective inhibitor (HAT inhibitor II) further increases MDR1 expression and drug efflux in the drug-resistant cells. Our data suggest that repeated exposure to chemotherapy may result in deregulated histone acetylation genome-wide and in the MDR1 promoter.

AB - Failure of chemotherapy in breast cancer presents a major problem and is often due to elevated expression of ATP binding cassette (ABC)-type transporters, such as MDR1 protein. It has been shown that MDR1/ABCB1 gene expression is regulated at the chromatin level by DNA methylation and histone acetylation. However, the modified histone residues have not been identified and the role of various histone acetyl transferases (HATs) is not fully understood. By studying a breast carcinoma model cell line and its MDR1-overexpressing derivative, we show that the histone 3 lysine 9 (H3K9) acetylation level is elevated 100-fold in the promoter and first exon of the MDR1 gene in the drug-resistant cell line compared to the drug-sensitive cell line. The acetylation level of the other examined lysine residues (H3K4, H3K14, H4K8, and H4K12) is weakly or not at all elevated in the MDR1 locus, although their acetylation is generally increased genome-wide in the drug-resistant cell. Downregulation of the expression of HATs PCAF and GCN5 by RNAi effectively reduces the expression of MDR1. Unexpectedly, treatment with a p300-selective inhibitor (HAT inhibitor II) further increases MDR1 expression and drug efflux in the drug-resistant cells. Our data suggest that repeated exposure to chemotherapy may result in deregulated histone acetylation genome-wide and in the MDR1 promoter.

UR - http://www.scopus.com/inward/record.url?scp=84859004082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859004082&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2012.02215.x

DO - 10.1111/j.1349-7006.2012.02215.x

M3 - Article

C2 - 22320423

AN - SCOPUS:84859004082

VL - 103

SP - 659

EP - 669

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 4

ER -